{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:27:21Z","timestamp":1793212041228,"version":"4.5.0"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2019,10,31]],"date-time":"2019-10-31T00:00:00Z","timestamp":1572480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,6,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Early discontinuation of infliximab (IFX) in pregnant women with inflammatory bowel disease (IBD) decreases the intrauterine fetal exposure to the drug but may increase the risk of disease flaring leading to poor pregnancy outcomes. In this study, we assessed the impact of early IFX discontinuation on mother\u2019s disease activity and on their at-risk babies.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>In a retrospective study of the Truven Health Analytics MarketScan database from 2011 to 2015, we compared IBD patients who discontinued IFX more than 90 days (\u201cearly IFX\u201d) with those who discontinue IFX 90 days or less (\u201clate IFX) before delivery. We evaluated the risk of flaring, defined by new steroid prescriptions, visits to emergency room and\/or hospital admissions, the pregnancy outcomes, and the at-risk babies.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>After IFX discontinuation, the early IFX group (68 deliveries) required significantly more steroid prescriptions than the late IFX group (318 deliveries) to control disease activity (P &amp;lt; 001). There were more preterm babies in the early IFX group (P &amp;lt; 049), but no difference within the 2 groups was noticed in the rate of intrauterine growth retardation, small for gestation, and stillborn babies. Similarly, there was no increase in acute respiratory infections, development delays, and congenital malformations in babies of the mothers from the late IFX vs early IFX groups.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Steroid-free remission IBD mothers are at risk for disease flares and preterm babies when IFX is discontinued early in pregnancy. Continuation of IFX seems to be safe at least for the first year of life.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ibd\/izz250","type":"journal-article","created":{"date-parts":[[2019,10,31]],"date-time":"2019-10-31T14:33:01Z","timestamp":1572532381000},"page":"1110-1117","source":"Crossref","is-referenced-by-count":29,"title":["Early Discontinuation of Infliximab in Pregnant Women With Inflammatory Bowel Disease"],"prefix":"10.1093","volume":"26","author":[{"given":"Brindusa","family":"Truta","sequence":"first","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ira L","family":"Leeds","sequence":"first","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA"},{"name":"Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph K","family":"Canner","sequence":"first","affiliation":[{"name":"Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan E","family":"Efron","sequence":"first","affiliation":[{"name":"Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandy H","family":"Fang","sequence":"first","affiliation":[{"name":"Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azah","family":"Althumari","sequence":"first","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bashar","family":"Safar","sequence":"first","affiliation":[{"name":"Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,10,31]]},"reference":[{"key":"2020061806433659800_CIT0001","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2147\/JIR.S165330","article-title":"Role of biologics and biosimilars in inflammatory bowel disease: current trends and future perspectives","volume":"11","author":"Rawla","year":"2018","journal-title":"J Inflamm Res."},{"key":"2020061806433659800_CIT0002","doi-asserted-by":"crossref","first-page":"765","DOI":"10.2174\/138920111795470903","article-title":"Transplacental transfer of immunosuppressants and biologics used for the treatment of inflammatory bowel disease","volume":"12","author":"Chaparro","year":"2011","journal-title":"Curr Pharm Biotechnol."},{"key":"2020061806433659800_CIT0003","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.cgh.2012.11.011","article-title":"Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease","volume":"11","author":"Mahadevan","year":"2013","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2020061806433659800_CIT0004","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1111\/j.1365-2036.2011.04617.x","article-title":"High intra-uterine exposure to infliximab following maternal anti-TNF treatment during pregnancy","volume":"33","author":"Zelinkova","year":"2011","journal-title":"Aliment Pharmacol Ther."},{"key":"2020061806433659800_CIT0005","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1053\/j.gastro.2016.04.002","article-title":"Concentrations of adalimumab and infliximab in mothers and newborns, and effects on infection","volume":"151","author":"Julsgaard","year":"2016","journal-title":"Gastroenterology."},{"key":"2020061806433659800_CIT0006","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/ajg.2011.5","article-title":"TNF-\u03b1 and the development of the neonatal immune system: implications for inhibitor use in pregnancy","volume":"106","author":"Arsenescu","year":"2011","journal-title":"Am J Gastroenterol."},{"key":"2020061806433659800_CIT0007","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.crohns.2010.05.001","article-title":"Case report: fatal case of disseminated BCG infection in an infant born to a mother taking infliximab for Crohn\u2019s disease","volume":"4","author":"Cheent","year":"2010","journal-title":"J Crohns Colitis."},{"key":"2020061806433659800_CIT0008","doi-asserted-by":"crossref","first-page":"e1189","DOI":"10.1542\/peds.2014-0054","article-title":"Anti-TNF-\u03b1 therapy may cause neonatal neutropenia","volume":"134","author":"Guiddir","year":"2014","journal-title":"Pediatrics."},{"key":"2020061806433659800_CIT0009","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.cgh.2012.10.024","article-title":"Effects of discontinuing anti-tumor necrosis factor therapy during pregnancy on the course of inflammatory bowel disease and neonatal exposure","volume":"11","author":"Zelinkova","year":"2013","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2020061806433659800_CIT0010","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/MIB.0000000000000596","article-title":"Use of immunomodulators and biologics before, during, and after pregnancy","volume":"22","author":"McConnell","year":"2016","journal-title":"Inflamm Bowel Dis."},{"key":"2020061806433659800_CIT0011","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1093\/ecco-jcc\/jju006","article-title":"The second European evidenced-based consensus on reproduction and pregnancy in inflammatory bowel disease","volume":"9","author":"van der Woude","year":"2015","journal-title":"J Crohns Colitis."},{"key":"2020061806433659800_CIT0012","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1053\/j.gastro.2015.12.003","article-title":"The Toronto consensus statements for the management of inflammatory bowel disease in pregnancy","volume":"150","author":"Nguyen","year":"2016","journal-title":"Gastroenterology."},{"key":"2020061806433659800_CIT0013","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1053\/j.gastro.2018.12.022","article-title":"Inflammatory bowel disease in pregnancy clinical care pathway: a report from the American gastroenterological association IBD Parenthood Project Working Group","volume":"156","author":"Mahadevan","year":"2019","journal-title":"Gastroenterology."},{"key":"2020061806433659800_CIT0014","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1038\/s41395-018-0176-7","article-title":"Continuous Anti-TNF\u03b1 use throughout pregnancy: possible complications for the mother but not for the fetus. a retrospective cohort on the French National Health Insurance Database (EVASION)","volume":"113","author":"Luu","year":"2018","journal-title":"Am J Gastroenterol."},{"key":"2020061806433659800_CIT0015","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1097\/MIB.0000000000001102","article-title":"The effect of disease activity on birth outcomes in a nationwide cohort of women with moderate to severe inflammatory bowel disease","volume":"23","author":"Kammerlander","year":"2017","journal-title":"Inflamm Bowel Dis."},{"key":"2020061806433659800_CIT0016","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.crohns.2012.04.009","article-title":"Management of inflammatory bowel disease in pregnancy","volume":"6","author":"Vermeire","year":"2012","journal-title":"J Crohns Colitis."},{"key":"2020061806433659800_CIT0017","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.cgh.2015.08.039","article-title":"Low risk of birth defects for infants whose mothers are treated with anti\u2013Tumor Necrosis Factor agents during pregnancy","volume":"14","author":"Br\u00f6ms","year":"2015","journal-title":"Clinical Gastroenterology and Hepatology"},{"key":"2020061806433659800_CIT0018"},{"key":"2020061806433659800_CIT0019","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","article-title":"Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data","volume":"43","author":"Quan","year":"2005","journal-title":"Med Care."},{"key":"2020061806433659800_CIT0020","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1080\/14767050410001668662","article-title":"Perinatal outcomes in inflammatory bowel disease","volume":"15","author":"Bush","year":"2004","journal-title":"J Matern Fetal Neonatal Med."},{"key":"2020061806433659800_CIT0021","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.2105\/AJPH.2005.065680","article-title":"Maternal obesity and diabetes as risk factors for adverse pregnancy outcomes: differences among 4 racial\/ethnic groups","volume":"95","author":"Rosenberg","year":"2005","journal-title":"Am J Public Health."},{"key":"2020061806433659800_CIT0022","first-page":"323","article-title":"Asthma in pregnancy","volume":"26","author":"Dewyea","year":"2005","journal-title":"Allergy Asthma Proc."},{"key":"2020061806433659800_CIT0023","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/S0002-9378(00)70225-0","article-title":"Risks of preeclampsia and adverse neonatal outcomes among women with pregestational diabetes mellitus. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units","volume":"182","author":"Sibai","year":"2000","journal-title":"Am J Obstet Gynecol."},{"key":"2020061806433659800_CIT0024","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0378-3782(01)00181-5","article-title":"MOS HIP: McMaster outcome study of hypertension in pregnancy","volume":"64","author":"Ray","year":"2001","journal-title":"Early Hum Dev."},{"key":"2020061806433659800_CIT0025","doi-asserted-by":"crossref","first-page":"781","DOI":"10.3982\/ECTA11293","article-title":"Matching on the estimated propensity score","volume":"84","author":"Abadie","year":"2016","journal-title":"Econometrica"},{"key":"2020061806433659800_CIT0026","doi-asserted-by":"crossref","first-page":"S170","DOI":"10.1016\/S0016-5085(14)60602-8","article-title":"Exposure to anti-TNF[alpha] therapy in the third trimester of pregnancy is not associated with increased adverse outcomes: results from the PIANO registry [abstract]","volume":"146","author":"Mahadevan","year":"2014","journal-title":"Gastroenterology."},{"key":"2020061806433659800_CIT0027","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S0016-5085(14)60001-9","article-title":"Achievement of developmental milestone among offspring of women with inflammatory bowel disease: the PIANO registry [abstract]","volume":"146","author":"Mahadevan","year":"2014","journal-title":"Gastroenterology."},{"key":"2020061806433659800_CIT0028","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1053\/j.gastro.2018.05.040","article-title":"Exposure concentrations of infants breastfed by women receiving biologic therapies for inflammatory bowel diseases and effects of breastfeeding on infections and development","volume":"155","author":"Matro","year":"2018","journal-title":"Gastroenterology."},{"key":"2020061806433659800_CIT0029","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1038\/s41395-018-0202-9","article-title":"Pregnancy outcomes reported during the 13-year TREAT registry: a descriptive report","volume":"113","author":"Lichtenstein","year":"2018","journal-title":"Am J Gastroenterol."},{"key":"2020061806433659800_CIT0030","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1097\/MIB.0000000000001234","article-title":"Anti-TNF-\u03b1 use during the third trimester of pregnancy in women with moderate-severe inflammatory bowel disease and the risk of preterm birth and low birth weight","volume":"23","author":"Kammerlander","year":"2017","journal-title":"Inflamm Bowel Dis."},{"key":"2020061806433659800_CIT0031","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1093\/ecco-jcc\/jjv234","article-title":"Anti-tumour necrosis factor \u03b1 therapies and inflammatory bowel disease pregnancy outcomes: a meta-analysis","volume":"10","author":"Shihab","year":"2016","journal-title":"J Crohns Colitis."},{"key":"2020061806433659800_CIT0032","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1053\/j.gastro.2013.09.061","article-title":"Limited risks of major congenital anomalies in children of mothers with IBD and effects of medications","volume":"146","author":"Ban","year":"2014","journal-title":"Gastroenterology."},{"key":"2020061806433659800_CIT0033","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.cgh.2015.08.039","article-title":"Low risk of birth defects for infants whose mothers are treated with anti-tumor necrosis factor agents during pregnancy","volume":"14","author":"Br\u00f6ms","year":"2016","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2020061806433659800_CIT0034","doi-asserted-by":"crossref","first-page":"635","DOI":"10.3899\/jrheum.080545","article-title":"A safety assessment of tumor necrosis factor antagonists during pregnancy: a review of the Food and Drug Administration database","volume":"36","author":"Carter","year":"2009","journal-title":"J Rheumatol."},{"key":"2020061806433659800_CIT0035","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1111\/j.1572-0241.2007.01355.x","article-title":"Disease activity in pregnant women with Crohn\u2019s disease and birth outcomes: a regional Danish cohort study","volume":"102","author":"N\u00f8rg\u00e5rd","year":"2007","journal-title":"Am J Gastroenterol."}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ibdjournal\/article-pdf\/26\/7\/1110\/33402594\/izz250.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ibdjournal\/article-pdf\/26\/7\/1110\/33402594\/izz250.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,18]],"date-time":"2020-06-18T10:53:29Z","timestamp":1592477609000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/26\/7\/1110\/5610578"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,31]]},"references-count":35,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2019,10,31]]},"published-print":{"date-parts":[[2020,6,18]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izz250","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,7]]},"published":{"date-parts":[[2019,10,31]]}}}